Source: Annual Congress 2004 - Gefitinib (Iressa) in NSCLC: A real alternative to chemotherapy
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
P. J. Souquet (Pierre-Benite, France). The importance of symptom improvement with gefitinib in NSCLC. Annual Congress 2004 - Gefitinib (Iressa) in NSCLC: A real alternative to chemotherapy

Member's Comments

No comment yet.

Related content which might interest you: Bevacizumab shows survival benefit for non-small lung cancer patients who received subsequent pemetrexed treatment but not had a therapeutic effect in clinical practice Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Efficacy and prognostic factors of first-line afatinib treatment for the EGFR-mutated non-small cell lung cancer in the real world Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 A study comparing the efficacy, quality of life and toxicity of cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer in the Indian scenario Source: Annual Congress 2011 - Palliation and morbidity in lung cancer patients Year: 2011 Systematic review of the effect of chemotherapy on quality of life (QoL) and symptom control in patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2006 - Lung cancer treatment Year: 2006 Treatment of patients with advanced non-small-cell lung cancer (NSCLC) with erlotinib: results from clinical practice Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 Quality of life in patients with advanced forms of NSCLC and breast cancer after induction chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 324s Year: 2005 Phase II study of S-1 with patient-reported outcome evaluation in elderly patients with previously untreated advanced non-small cell lung cancer Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017 Efficacy and safety of Pemetrexed (PEM) for elderly patients with advanced non-small cell lung cancer (NSCLC) who had previous chemotherapy Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer Source: Eur Respir J 2006; 27: 895-901 Year: 2006 Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy Source: Eur Respir J 2016; 48: 861-872 Year: 2016 Cost-effectiveness analysis of afatinib vs gefitinib in EGFR-Mutated population with advanced non-small-cell lung cancer Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 The correlation between clinical and pathomorphological impacts of induction chemotherapy and long-term results of multimodality treatment for IIIA stage non-small cell lung cancer Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 Source: Eur Respir J 2011; 39: 172-179 Year: 2012 Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 Source: Eur Respir J 2012; 39: 172-179 Year: 2012 Erlotinib as salvage treatment after failure to gefitinib in non-small cell lung cancer Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Safety and tolerability of gefitinib in advanced NSCLC: overview of clinical experience Source: Eur Respir J 2003; 22: Suppl. 45, 32s Year: 2003 Correlation between parameters of quality of life in patients with non-small cell lung cancer treated by chemotherapy and radiotherapy Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology Year: 2007 Comparison of quality of life in patients with non-small cell lung cancer treated by chemotherapy or radiotherapy Source: Eur Respir J 2004; 24: Suppl. 48, 75s Year: 2004